Overview

• Pfizer raised its 2025 adjusted EPS guidance by $0.10 to $2.90–$3.10 after reporting Q2 revenue up 10% year over year to $14.7 billion.
• The company expanded its multi-year cost-savings plan by $1.7 billion to a $7.7 billion total target, with about $4.5 billion expected by the end of 2025.
• Income metrics remain a focus, with 15 consecutive years of dividend increases, a $0.43 quarterly payout, and a yield near 7.2% in late September.
• Growth hopes center on oncology, including 18 phase 3 programs and eight candidates projected to exceed $1 billion in annual sales by 2030, plus assets such as Elrexfio and sigvotatug vedotin showing clinical and regulatory progress.
• Pfizer and BioNTech reported Phase 3 immunogenicity data for the 2025–2026 COVID-19 vaccine showing at least four-fold higher neutralizing antibodies in older and high-risk adults, with data submitted to the FDA to support authorization.